Memaben

Memantine Hydrochloride, the active ingredient in Memaben, is a NMDA receptor antagonist presented as a tablet for oral use. It is indicated for the treatment of Alzheimer’s disease in adult patients. GNH USA supplies Memaben as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memaben is an NMDA receptor antagonist used in the management of Alzheimer’s disease, a neurodegenerative disorder affecting cognition and function. - Alzheimer’s disease (mild to moderate): improves cognitive performance and daily living activities. - Alzheimer’s disease (moderate): helps maintain functional abilities and slows symptomatic decline. - Alzheimer’s disease (as adjunct to cholinesterase inhibitors): provides additional symptomatic benefit when combined with standard therapy.

Memaben may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Confusion: temporary disorientation. - Fatigue: feeling unusually tired. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Hallucinations: visual or auditory disturbances. - Cardiac arrhythmia: irregular heart rhythm that may be life‑threatening.

Before initiating Memaben, several safety considerations should be reviewed. - Renal impairment: assess kidney function and adjust therapy if necessary. - History of seizures: monitor closely for increased seizure activity. - Concurrent NMDA agonists: avoid use as they may counteract therapeutic effect. - Pregnancy: prescribe only when potential benefit justifies potential risk to the fetus. - Elderly patients: watch for heightened confusion or falls. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memaben can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Amantadine: may diminish memantine’s therapeutic effect. - Ketamine: additive NMDA antagonism could increase neuro‑psychiatric adverse events. - Mefenamic acid: may heighten dizziness and hypotension.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may worsen cognitive impairment. - Central nervous system depressants (e.g., benzodiazepines): can enhance sedation and dizziness.